At the 2021 annual congress of the European Society of Medical Oncology (ESMO 2021), South Korea’s Samsung Bioepis has announced five-year follow-up data for On 14 September 2021
Indian drugmaker Intas Pharmaceuticals has been granted rights to commercialize DMB-3115, a proposed biosimilar to Janssen’s Stelara (ustekinumab), in all globa 26 July 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.